Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30968983 | 0.91 | RXFP1 (0.39) | LMNATSHRTP53ALOX15HTT | |
| SCHEMBL3831039 | 0.80 | ADORA3 (0.53) | SLC29A1MAPK1 | |
| SCHEMBL29401884 | 0.80 | ADORA3 (0.53) | SLC29A1MAPK1 | |
| SCHEMBL30950292 | 0.80 | TARS1 (0.37) | SLC29A1 | |
| SCHEMBL17627818 | 0.75 | RXFP1 (0.39) | LMNATSHRTP53ALOX15HTT | |
| SCHEMBL30705001 | 0.75 | RXFP1 (0.39) | LMNATSHRTP53ALOX15HTT | |
| SCHEMBL31031049 | 0.73 | SLC29A1 (0.39) | LMNATSHRRXFP1SLC29A1MAPT | |
| SCHEMBL28662239 | 0.73 | ADORA2A (0.38) | LMNATP53HTTSLC29A1CYP3A4 | |
| SCHEMBL27498338 | 0.71 | TP53 (0.42) | LMNATSHRTP53ALOX15HTT | |
| SCHEMBL1934654 | 0.70 | ADORA3 (0.53) | SLC29A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114206909-A | Therapeutic viral vaccines | 葛兰素史克生物有限公司 | 2022-03-18 | — | — | CN | disclosed |
| CN-113874503-A | Systems and methods for modulating CRISPR activity | 辛瑟高公司 | 2021-12-31 | — | — | CN | disclosed |
| CN-113840926-A | Method for preparing lipid-encapsulated RNA nanoparticles | 阿克丘勒斯治疗公司 | 2021-12-24 | — | — | CN | disclosed |
| CN-113677793-A | Stable CRISPR complexes | 辛瑟高公司 | 2021-11-19 | — | — | CN | disclosed |
| CN-113164584-A | Immunogenic compositions and uses thereof | 葛兰素史密丝克莱恩生物有限公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-111848712-A | End-capped nucleic acid molecules | 诺华股份有限公司 | 2020-10-30 | — | — | CN | disclosed |
| CN-111108203-A | Rabies virus antigen constructs | 葛兰素史密丝克莱恩生物有限公司 | 2020-05-05 | — | — | CN | disclosed |
| CN-110891553-A | Method for producing liposome encapsulating RNA | 葛兰素史密丝克莱恩生物有限公司 | 2020-03-17 | — | — | CN | disclosed |
| CN-110201187-A | Modified nucleosides, nucleotide and nucleic acid compositions | 现代泰克斯公司 | 2019-09-06 | — | — | CN | disclosed |
| CN-104968354-A | Methods of increasing the viability or longevity of an organ or organ explant | modeRNA Therapeutics | 2015-10-07 | — | — | CN | disclosed |
| CN-104531812-A | Engineered nucleic acids and methods of use thereof | MODERNA THERAPEUTICS INC | 2015-04-22 | — | — | CN | disclosed |
| CN-104531671-A | Engineered nucleic acids and methods of use thereof | MODERNA THERAPEUTICS INC | 2015-04-22 | — | — | CN | disclosed |